dr. cella on the side effect focus of the axitinib and sorafenib trial
Published 13 years ago • 297 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
1:05
dr. cella on the value of patient-reported outcomes
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:44
dr. cella on patient-reported outcomes in a clinical setting
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
0:44
dr. rini on the axitinib and sorafenib trial vegf focus
-
2:16
axitinib showed two-month advantage to sorafenib
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:51
dr. cella explains the increase in quality of life assessments
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
0:38
dr. rini explains the axitinib integration process
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:44
dr. cella describes patient assessment reference scores
-
0:53
dr. cella on quality of life assessments' cost effectiveness
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc